TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Sponsor: LigaChem Biosciences, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05941507 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05941507 Rescue Dossier →